Abstract: Objective To explore the efficacy and toxic reaction of three-dimensional conformal radiotherapy（3DCRT） with chemotherapy for advanced esophageal cancer. Methods From September 2011 to April 2013， 42 patients were treated by 3DCRT（DT：60 Gy） and concurrent chemotherapy using raltitrexed（3 mg/m2， d1） and oxalipatin（130 mg/m2， d2） with a 28-day cycle. The concurrent chemotherapy lasted for 2 cycles.After radiotherapy， 2 cycles of the same regimen for consolidation chemotherapy were used 4-6 weeks later. Results All patients finished the radiochemotherapy and got complete remission in 18 cases（42.9%）， partial remission in 23 cases（54.8%）and stable disease in 1 case（2.4%） with the rate of total efficiency of 97.6%. The 1-and 2-year local control rates and survival rates were 90.5%， 71.4% and 85.7%， 60.7%. Main side effects were grade 1-2. The incidence of acute esophagitis， acute radiation pneumonia， gastrointestinal reaction， bone marrow depression and liver function injury were 95.2%， 23.8%， 73.8%， 42.9% and 19.1%, respectively. Conclusion Raltitrexed and oxalipatin combined with 3DCRT for advanced esophageal cancer patients is effective and well-tolerated. The value of addition of concurrent radiochemotherapy for advanced esophageal cancer needs further investigation.